Amphastar Pharmaceuticals (AMPH) EV to EBITDA (2014 - 2026)

Amphastar Pharmaceuticals has reported EV to EBITDA for 13 years, with the latest figure at 14.3 in Q2 2026.

• On a quarterly basis, EV to EBITDA fell 27.81% year-over-year to 14.3 in Q2 2026; TTM through Jun 2026 was 4.97, a 8.08% increase from a year earlier, with the FY2025 full-year figure at 6.69, down 11.11% from the prior year.
• EV to EBITDA was 14.3 for Q2 2026 at Amphastar Pharmaceuticals, down from 42.74 in the prior quarter.
• The five-year high for EV to EBITDA was 72.32 in Q1 2022, with the low at 14.3 in Q2 2026.
• Average EV to EBITDA over 5 years is 40.27, with a median of 37.32 recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: EV to EBITDA soared 62.38% in 2023, then plunged 55.98% in 2024.
• Over 5 years, EV to EBITDA stood at 30.99 in 2022, then jumped by 62.38% to 50.32 in 2023, then slumped by 31.93% to 34.25 in 2024, then decreased by 22.97% to 26.39 in 2025, then plunged by 45.8% to 14.3 in 2026.
• The last three EV to EBITDA figures came in at 14.3 (Q2 2026), 42.74 (Q1 2026), and 26.39 (Q4 2025), per Business Quant data.